- Vatalanib base
-
- $10.00 / 1ASSAYS
-
2026-01-24
- CAS:212141-54-3
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 1 ton
- Vatalanib free base
-
- $40.00 / 5mg
-
2026-01-20
- CAS:212141-54-3
- Min. Order:
- Purity: 99.52%
- Supply Ability: 10g
- Vatalanib base
-
- $1.00 / 100g
-
2019-12-24
- CAS:212141-54-3
- Min. Order: 100g
- Purity: 98%min
- Supply Ability: G/KG/T
|
| | Vatalanib base Basic information |
| Product Name: | Vatalanib base | | Synonyms: | N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)- 1-Phthalazinamine;1-PhthalazinaMine, N-(4-chlorophenyl)-4-(4-pyridinylMethyl)-;Vatalanib (PTK787) Dihydrochloride Base;Pynasunate, ZK222584, CGP-79787, PTK 787;(4-Chloro-phenyl)-(4-pyridin-4-ylmethyl-phthalazin-1-yl)-amine;Vatalanib free base (PTK787 free base;PTK787 free base | | CAS: | 212141-54-3 | | MF: | C20H15ClN4 | | MW: | 346.81 | | EINECS: | 202-303-5 | | Product Categories: | Antineoplastic | | Mol File: | 212141-54-3.mol |  |
| | Vatalanib base Chemical Properties |
| Melting point | 209-212° | | Boiling point | 587.8±50.0 °C(Predicted) | | density | 1.330±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C(protect from light) | | solubility | ≥16.85 mg/mL in DMSO; ≥3.0125 mg/mL in EtOH with gentle warming and ultrasonic; ≥32.53 mg/mL in H2O with gentle warming and ultrasonic | | pka | 5.46±0.10(Predicted) | | form | solid | | color | Light yellow to yellow |
| | Vatalanib base Usage And Synthesis |
| Uses | Vatalanib (PTK787) is an inhibitor of VEGFR2/KDR, Flt-1 and c-Kit with IC50 of 37 nM, 77 nM and 730 nM, respectively. | | Uses | anti-viral | | Definition | ChEBI: A member of the class of phthalazines that is phthalazine in which the hydrogens at positions 1 and 4have been replaced by a p-chlorophenylamino group and a pyridin-4-ylmethyl group, respectively. It is a multi-targeted tyrosine kinase inhibit
r for all isoforms of VEGFR, PDGFR and c-Kit. | | in vivo | Vatalanib induces dose-dependent inhibition of the angiogenic response to VEGF and PDGF in both a growth factor implant model and a tumor cell-driven angiogenesis model after once-daily oral dosing (25-100 mg/kg). In the same dose range, Vatalanib also inhibits the growth and metastasesof several human carcinomas in nude mice without significant effect on circulating blood cells or bone marrow leukocytes[1]. | | IC 50 | VEGFR2: 37 nM (IC50) |
| | Vatalanib base Preparation Products And Raw materials |
|